Pomegranate derived punicalagin and urolithin could be the real deal when it comes to heart health, but just eating pomegranates isn't enough
The post Punicalagin Derivatives Pack a Punch When It Comes to Heart Disease appeared first on Medical News Bulletin.
Healthcare providers in 2026 need systems that improve care delivery without increasing operational complexity. Clinics must process information quickly, coordinate across teams, and maintain accuracy at every step. Many organizations turn to a custom healthcare software development service to build solutions that reflect real-world clinical workflows rather than adapting to rigid systems. Cleveroad develops secure […]
The post How Custom Healthcare Software Development Improves Patient Care in 2026 appeared first on Medical News Bulletin.
The time of watching a family member grow older should be one of peace and connection. Selecting a Duluth, GA long-term care facility means you are trusting that your loved one gets the dignity and medical care they deserve. That said, remaining vigilant is the best return there is for betting on trust with the […]
The post Spotting Early Signs of Medical Neglect in Nursing Homes appeared first on Medical News Bulletin.
CHICAGO — Three years after NordICC trial’s much-debated 10-year results were published, follow-up data showed colonoscopy screening reduced colorectal cancer incidence by about 30% but did not reduce mortality in this patient population.
The new findings were presented at Digestive Disease Week and simultaneously published in The Lancet.
“The first publication at 10 years showed an effect of around 20% risk reduction and no effect on [mortality],” principal investigator and presenter Michael Bretthauer, MD, PhD, professor of medicine at the University of Oslo, told Healio. “Some experts said
CHICAGO — The number of annual colonoscopies performed in the U.S. is projected to decline over the next decade as use of noninvasive colorectal cancer screening options continues to rise, data presented at Digestive Disease Week showed.
While colonoscopy remains the gold standard in CRC screening and prevention, the rise in use of noninvasive tests is giving average-risk patients new ways to screen for cancer, Lyndon V. Hernandez, MD, MPH, a gastroenterologist at GI Associates, told Healio.
Colonoscopies are also still the most cost-effective screening method for colorectal cancer, results of
Suneel Kamath, MD, knows too well the sense of helplessness that comes with living through what he calls “the doughnut hole.”
After compelling data from a late-stage trial are presented at a major medical meeting or published in a peer-reviewed journal, excitement about a potentially practice-changing treatment spreads like wildfire through the clinical community and the findings support a new drug application to the FDA.
Then, a monthslong wait begins.
“During this time, the trials are all closed, the drug is not on the market and nobody can get it,” Kamath, a gastrointestinal oncologist at
The FDA approved a supplemental biologics license application for Asceniv, expanding its use to younger patients with primary humoral immunodeficiency, according to a press release.
Prior to this approval, the release noted that the prescribing information for Asceniv (ADMA Biologics), a plasma-derived, polyclonal, intravenous immunoglobulin therapy, said it was only available for patients with primary humoral immunodeficiency aged at least 12 years. Now, it is available for patients aged at least 2 years.
Asceniv first received FDA approval in April 2019, according to the release.
“Respiratory
DENVER — Using visual prompts helped improve glaucoma detection by a large language model, according to a poster presentation at the Association for Research in Vision and Ophthalmology meeting.
Iris Fang-Yu Hu, MD, and colleagues wanted to find out if giving a general-purpose large language model visual examples could help it detect glaucoma in fundus photos. They compared this “in-context learning” in two large language models with prompts without any reference images, according to the study.
“A large language model is actually quite a powerful tool for glaucoma detection,” Hu told Healio.
CHICAGO — Restarting subcutaneous infliximab 240 mg after treatment interruption of at least 16 weeks was able to recapture response early, with sustained biochemical and endoscopic improvements over time, according to a presenter here.
Data presented at Digestive Disease Week showed that early clinical responses were observed as early as 8 ± 2 weeks after reintroduction of 240 mg subcutaneous infliximab (Zymfentra, Celltrion).
“Historically, patients may have discontinued IV infliximab for a multitude of reasons, such as insurance, tolerance, anti-drug antibodies or pharmacokinetic reasons,”
COPENHAGEN, Denmark —In this Healio video, Balazs Halmos, MD, MS, discusses results from the TOP trial, presented at European Lung Cancer Congress.
The phase 3 trial compared osimertinib (Tagrisso, AstraZeneca) plus chemotherapy with osimertinib alone in 294 patients with previously untreated nonsquamous non-small cell lung cancer with concurrent EGFR and TP53 mutations.
“Chemotherapy adds substantial value to osimertinib in terms of basically doubling the progression free survival,” Halmos, director of thoracic oncology and clinical cancer genomics at Montefiore Einstein Cancer Center, said.